期刊文献+

miR21抑制剂对肺腺癌细胞A-549的抑制效果

Inhibition of miR21 inhibitor on A-549 cells in vitro
暂未订购
导出
摘要 目的探讨miR21抑制剂转染人肺腺癌细胞A-549对其体外侵袭及血管形成能力的影响。方法 miR21抑制剂转染A-549细胞,同时设置未转染的A-549细胞作为对照组,转染24、48、72及96 h后,四甲基偶唑氮法(MTT)法检测两组细胞增殖抑制率;Transwell方法检测miR21抑制剂对A-549细胞侵袭的影响;小管形成实验检测miR21抑制剂对血管形成的影响。结果转染24 h,两组抑制率比较,差别无统计学意义;转染48 h及以后,抑制剂组抑制率均高于对照组,差别有统计学意义(P<0.05)。Transwell检测结果显示miR21抑制剂组每个视野细胞数(11.60±5.32)个远少于对照组(107.60±3.21)个,两组差别有统计学意义(P<0.01)。抑制剂组每视野小管计数平均(159.30±0.51)个,远少于对照组(508.80±1.30)个,两组差别有统计学意义(P<0.01)。结论 miR21抑制剂能够明显抑制A-549的侵袭能力,并能明显抑制血管内皮细胞血管生成,提示miR21抑制剂可以作为潜在的肺癌基因治疗的新方法。 Objective To study the inhibition of miR21 inhibitor on the invasion and anti-angiogenesis of A-549 cells.Methods MiR21 inhibitor was transfected into A-549,and the control group was set up.24,48,72,96 hours after transfection,the effect of growth suppressing was quantified by 3-2 (4,5-dimethylthiazol-2-yl) 2,5-diphenyltetrazolium bromide (MTF) assay,anti-invasion was observed by transwell assay.Tube formation assay was used to detect the effects of miR21 inhibitor on human umbilical vein endothelial cells (HUVEC) angiogenesis.Results Twenty-four hours after transfection,the suppressing rate was different between the two groups;48,72,96 h after transfection,the suppressing rates in inhibition group were higher than those in control group,the difference was statistically significant (P 〈 0.05).By transwell assay,number of cells in inhibition group (11.60 ± 5.32) was less than that in control group (107.60 ± 3.21),the difference was statistically significant (P 〈 0.01).Tubes in inhibition group (159.30 ± 0.51) was less than that in control group (508.80 ± 1.30),the difference was statistically significant(P 〈0.01).Conclusions miR21 inhibitor can inhibit the invasion of A-549 and angiogenesis of HUVEC.miR21 inhibitor can be a potential gene-therapy for gastric carcinoma.
出处 《武警医学》 CAS 2014年第5期500-502,506,共4页 Medical Journal of the Chinese People's Armed Police Force
关键词 miR21抑制剂 细胞侵袭 血管形成 肺腺癌 miRNA21 inhibitor invasion angiogenesis lung adenocarcinoma
  • 相关文献

参考文献10

  • 1Vimalraj S, Miranda P J, Ramyakrishna B, et al. Reg ulation of breast cancer and bone metastasis by MicroR NAs[J]. Dis Markers, 2013, 35(5): 369-387.
  • 2Li J, Xu J, Cheng Y, et al. Circulating micro RNAs as mirrors of acute coronary syndromes: MiRacle or quag- Mire? [J]. J Cell Mol Med, 2013, 4(11) : 564-568.
  • 3Song G, Xu G, Ji C, et al. The role of micro RNA-26b in human adipocyte differentiation and proliferation [ J ]. Gene ,2014,533 ( 2 ) : 481-487.
  • 4Abu-Halima M, Backes C, Leidinger P, et al. MicroR- NA expression profiles in human testicular tissues of in- fertile men with .different histopalhologic patterns [ J ]. Fertil Steril,2014, 101 ( 1 ) : 78-86.
  • 5Cortinovis D, Monica V, Pietrantonio F, et al. MicroR- NAs in non-small cell lung cancer: current status and future therapeutic promises [ J ]. Curr Pharm Des, 2013, 19(35):5961-5966.
  • 6周彩存,任胜祥.肺癌非手术治疗进展[J].中国实用内科杂志,2007,27(1):5-7. 被引量:8
  • 7Kang H Y. MicroRNA-21 regulates stemness in cancer cells[J]. Stem Cell Res Ther,2013,4(5) : 110-113.
  • 8Cancer Genome Atlas Research Network. Comprehen- sive molecular characterization of clear cell renal cell carcinoma [J]. Nature,2013, 499(7456) : 43-49.
  • 9Risbud R M, Lee C, Porter B E. Neurotrophin-3 mRNA a putative target of miR21 following status epilepticus [J]. Brain Res, 2011, 18(1424): 53-59.
  • 10Sheth S, Jajoo S, Kaur T, et al. Resveratrol reduces prostate cancer growth and metastasis by inhibiting the Akt/MicroRNA-21 pathway [ J]. PLoS One, 2012,7 (12) :51655-51660.

二级参考文献15

  • 1周彩存,徐瑛.非小细胞肺癌辅助化疗研究进展[J].国外医学(呼吸系统分册),2005,25(10):787-789. 被引量:3
  • 2Takada M,Fukuoka M,Kawahara M,et al.Phase Ⅲ study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer:results of the Japan Clinical Oncology Group Study 9104[J].J Clin Oncol,2002,20 (14):3054-3060.
  • 3Fried DB,Morris DE,Poole C,et al.Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer[J].J Clin Oncol,2005,23 (1):248.
  • 4De Ruysscher D,Pijls -Johannesma M.Systematic review and meta-analysis of randomised,controlled trials of the timing of chest radiotherapy in patients with limited-stage,small-cell lung cancer[J].Ann Oncol,2006,17 (4):543-552.
  • 5Noda K,Nishiwaki Y,Kawahara M,et al.Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer[J].N Engl J Med,2002,346 (2):85-91.
  • 6Hanna N,Bunn PA Jr,Langer C,et al.Randomized phase Ⅲ trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive -stage disease small -cell lung cancer[J].J Clin Oncol,2006,24 (13):2038-2043.
  • 7Schiller JH,Adak S,Cella D,et al.Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer:E7593-a phase Ⅲ trial of the Eastern Cooperative Oncology Group[J].J Clin Oncol,2001,19:2114-2122.
  • 8Pignon JP,Tribodet H,Scagliotti GV,et al.Lung adjuvant cisplatin evaluation (LACE):a pooled analysis of five randomized clinical trials including 4 584 patients[J].J Clin Oncol,2006 ASCO abstract:7008.
  • 9Strauss GM,Herndon JE,Maddaus MA,et al.Adjuvant chemotherapy in stage IB non -small cell lung cancer (NSCLC):update of cancer and leukemia group B (CALGB) protocol 9633[J].J Clin Onco,2006 ASCO abstract:7007.
  • 10Vokes EE,Herndon JE,Crawford J,et al.Randomized phase Ⅱ study of cisplatin with gemcitabine plus paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage ⅢB non-small -cell lung cancer:cancer and leukemia group B study 9431[J].J Clin Oncol,2002,20 (20):4191-4198.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部